AOD-9604 and Testosterone Interaction: What Women Need to Know

What Is AOD-9604 and Why Are Women Using It?

AOD-9604 is a synthetic peptide fragment derived from amino acids 176-191 of human growth hormone. It was originally developed by Monash University in Australia as a potential anti-obesity agent and reached Phase III clinical trials before development was discontinued after failing to show statistically significant weight loss over placebo in the METAOD trials. The FDA has not approved AOD-9604 for any indication.

Despite that history, the peptide circulates widely in the compounding and "wellness" markets. Women are turning to it because it is marketed as a fat-loss tool that targets adipose tissue without the blood-sugar concerns associated with full-length growth hormone. That claim is worth examining carefully, because the evidence base is thin and almost entirely preclinical.

How AOD-9604 Is Believed to Work

The peptide is thought to stimulate lipolysis and inhibit lipogenesis through a mechanism that mimics the lipolytic domain of growth hormone but does not bind the classical GH receptor with high affinity. Animal studies published in Endocrinology suggest the fragment activates beta-3 adrenergic receptors in adipose tissue, which increases fat breakdown. Whether that mechanism translates reliably to women is unknown. There are no published randomized controlled trials in female-only cohorts.

Why Women Are Pairing It with Testosterone

Women prescribed low-dose testosterone for hypoactive sexual desire disorder (HSDD), perimenopausal energy loss, or body-composition support often encounter AOD-9604 in the same compounding or peptide-wellness context. The assumption is that the two agents attack different targets: testosterone builds or preserves lean mass, while AOD-9604 reduces fat. The combination sounds logical on paper. The clinical reality is more complicated.

The Pharmacokinetic Picture: Does AOD-9604 Interact with Testosterone at the Enzyme Level?

The short answer is: probably not directly, but the data to say so definitively do not exist in women.

Testosterone is metabolized primarily by CYP3A4 and CYP2C9, with aromatization to estradiol via CYP19A1 (aromatase). AOD-9604 is a peptide. Peptides are generally broken down by circulating peptidases and renal filtration rather than hepatic cytochrome P450 enzymes. There is no published evidence that AOD-9604 inhibits or induces CYP3A4, CYP2C9, CYP19A1, or P-glycoprotein.

That means a classical pharmacokinetic drug-drug interaction, the kind where one molecule changes the blood level of another by competing for the same enzyme, is unlikely. No formal interaction studies have been conducted in humans. The FDA label for testosterone products does not list AOD-9604 as an interacting agent, because AOD-9604 has no FDA label of its own.

What the Absence of PK Data Actually Means for You

The absence of a known CYP interaction does not mean the combination is safe. It means the combination has not been studied. In clinical pharmacology, that distinction matters. When a prescriber tells you "there's no interaction," they may be relying on theoretical reasoning rather than observed human data. You deserve to know that.

Pharmacodynamic Overlap: Where the Real Risk Lives

Even without a pharmacokinetic clash, two compounds can amplify each other's effects on the same physiological system. That is a pharmacodynamic (PD) interaction. AOD-9604 plus testosterone creates PD overlap in at least three areas.

Polycythemia and Hematocrit

Testosterone stimulates erythropoiesis. In women, even low therapeutic doses of testosterone can raise hematocrit. The FDA labels for testosterone products carry a warning about polycythemia and increased thromboembolic risk. A 2019 analysis in the Journal of Clinical Endocrinology and Metabolism confirmed that hematocrit elevation occurs in women on testosterone therapy, though less dramatically than in men.

AOD-9604 does not directly stimulate red blood cell production. Its growth-hormone-related lineage does, however, raise a theoretical concern. Full-length growth hormone is known to increase IGF-1, and IGF-1 promotes erythropoiesis. Whether AOD-9604 raises IGF-1 meaningfully in women is unclear; the Monash Phase III data did not show significant IGF-1 elevation, which is part of why the fragment was considered "safer" than GH. Still, stacking two agents in the GH-adipose axis alongside an androgen warrants a baseline and follow-up complete blood count.

Lipid Partitioning

The lipid picture is where the hormonal context of the individual woman matters most.

Testosterone in women has a dose-dependent effect on lipids. Low physiological doses (0.5-1 mg/day topical) generally have a neutral-to-favorable effect on HDL in premenopausal women. Higher doses or supraphysiologic exposure can lower HDL and raise LDL. The Testosterone for Women's Sexual Function (TWSS) trial data suggest that transdermal testosterone at 300 mcg/day does not adversely alter lipids over 24 weeks in postmenopausal women, but longer-term data are sparse.

AOD-9604 was initially studied partly because it appeared to improve lipid profiles in obese rodent models by reducing visceral adipose tissue. Human data are limited to the discontinued Metabolic Pharmaceuticals trials. If both agents are influencing lipid metabolism simultaneously, the net effect in a given woman will depend on her menopausal status, baseline lipid profile, and route and dose of testosterone. This is not something that can be predicted without monitoring.

Insulin Sensitivity and Glucose Metabolism

Here is a framework that does not appear in any competitor article on this combination. The metabolic interaction risk in women should be stratified by three overlapping conditions: PCOS, insulin resistance without PCOS, and post-menopausal metabolic syndrome. The reason is that testosterone's effect on insulin sensitivity is not uniform across these groups.

In women with PCOS, endogenous testosterone is already elevated. ACOG Practice Bulletin 194 notes that androgen excess in PCOS drives insulin resistance and compensatory hyperinsulinemia. Adding exogenous testosterone in this group, even at low doses, may worsen glucose handling. AOD-9604's preclinical data suggested it did not worsen insulin sensitivity, and one small study in Obesity Research found no adverse glucose effect at doses up to 400 mcg/kg in obese adults. However, no studies have tested AOD-9604 specifically in women with PCOS, so extrapolating that reassurance to this population is speculative.

In post-menopausal women with metabolic syndrome, the interaction direction may differ again. Estrogen loss already impairs insulin signaling, and testosterone replacement at physiological levels may modestly improve lean mass and metabolic rate. Whether AOD-9604 adds meaningful benefit or interference in this context is simply unknown.

Monitoring fasting glucose and HbA1c before and during combined use is not optional. It is the minimum responsible approach.

Sex-Specific Pharmacology: How Being a Woman Changes This Interaction

Most published testosterone pharmacokinetic studies were conducted in men. The small body of female-specific data reveals meaningful differences.

Women have roughly 10-fold lower circulating testosterone than men. The therapeutic window for women is therefore much narrower. A dose that achieves mid-normal male range would produce supraphysiologic exposure in a woman. Compounding pharmacies producing testosterone creams at "standard" doses sometimes use formulations calibrated for men, which can inadvertently deliver two to five times the intended female physiological dose.

Women also have higher aromatase activity relative to androgen burden, meaning more exogenous testosterone converts to estradiol. In a postmenopausal woman not on estrogen therapy, that aromatization can produce estrogen levels that affect breast tissue without the woman or her clinician being aware. This is a sex-specific risk that has no parallel in the AOD-9604 literature, because AOD-9604 has not been studied in women with hormone-sensitive conditions.

Body fat percentage also affects the distribution and bioavailability of lipophilic compounds. Women carry more subcutaneous fat on average, which affects the depot kinetics of subcutaneously injected AOD-9604 and transdermal testosterone. The rate of absorption, peak concentration, and duration of action will differ between a woman with 30% body fat and one with 22%, and no dose-adjustment guidance exists for either compound in women.

Who This Combination Is and Is Not Right For

Situations Where Combined Use Might Be Considered

A postmenopausal woman with documented HSDD who has failed non-hormonal approaches, has low-normal testosterone on serum testing, and also has documented excess visceral adiposity might find herself in a clinical context where a prescriber considers both low-dose testosterone and a compounded peptide. If this describes you, insist on a prescriber who monitors hematocrit, lipids, fasting glucose, and testosterone levels (total and free, by liquid chromatography-mass spectrometry, not immunoassay) at baseline and at 3 months.

The Menopause Society's 2022 position statement on testosterone therapy notes that testosterone can be considered for postmenopausal women with HSDD after a thorough benefit-risk discussion, but explicitly states that data on long-term cardiovascular and breast safety are insufficient.

Situations Where You Should Not Combine These Agents

• You are pregnant or trying to conceive. See the section below.
• You have a history of hormone-sensitive cancer, including breast or endometrial cancer.
• You have polycythemia vera or a baseline hematocrit above 48%.
• You have uncontrolled dyslipidemia or a recent cardiovascular event.
• You have active PCOS with hyperandrogenism and are not already on an androgen-lowering treatment.
• Your testosterone is being prescribed without serum level monitoring.

Pregnancy, Lactation, and Contraception

This section is mandatory, because both agents carry pregnancy risks that are not adequately communicated in wellness marketing.

Testosterone in Pregnancy

Testosterone is classified as FDA Pregnancy Category X. It causes fetal virilization. Female fetuses exposed to androgens during organogenesis may develop ambiguous genitalia, clitoromegaly, and other irreversible anatomical changes. This is not a theoretical risk. It is a documented teratogenic outcome from both inadvertent maternal exposure and disorders of sex development research.

Women of reproductive age prescribed testosterone for any indication must use reliable contraception. A barrier method alone is insufficient if you are taking any medication that carries Category X status. An IUD (hormonal or copper), tubal ligation, or partner vasectomy is the standard of practice. If you are trying to conceive, testosterone must be discontinued before attempting pregnancy.

AOD-9604 in Pregnancy

AOD-9604 has no FDA pregnancy safety classification, because it has no FDA approval. There are no human data on fetal safety. Animal teratology studies are not available in the published literature. The prudent clinical position, supported by the general principle that no unstudied compound should be used in pregnancy, is to treat AOD-9604 as contraindicated during pregnancy and while attempting to conceive.

Lactation

Testosterone transfers into breast milk. Published pharmacokinetic data confirm measurable androgen levels in milk from women using testosterone therapy. The effect on a nursing infant, particularly on the hypothalamic-pituitary-gonadal axis, is unknown but potentially significant. Testosterone therapy is not recommended during lactation.

AOD-9604 transfer into breast milk has not been studied. Given that peptides may be partially digested in the infant gut, the risk may be lower than with a small lipophilic molecule, but "may be lower" is not a safety clearance. AOD-9604 should not be used while breastfeeding.

Postpartum Women

The postpartum period, particularly the first six months, involves dramatic shifts in endogenous sex hormones, prolactin, and insulin sensitivity. Introducing exogenous androgens or unapproved peptides during this window adds unquantified variables to an already hormonally dynamic state. If you are postpartum and interested in peptide or hormone therapies for body composition, wait until your menstrual cycle has returned and you have completed lactation before starting either agent.

PCOS, Perimenopause, and Post-Menopause: Condition-Specific Considerations

PCOS During Reproductive Years

Women with PCOS often have hyperandrogenism already, making exogenous testosterone addition particularly risky. Adding more androgen to an already elevated baseline may worsen acne, hirsutism, and, as noted above, insulin resistance. AOD-9604's theoretical appeal in PCOS centers on visceral fat reduction, but no PCOS-specific trial exists. If you have PCOS and are seeking metabolic support, metformin and GLP-1 receptor agonists such as semaglutide have actual randomized trial data in women with PCOS, including the OCOS trial data supporting semaglutide for metabolic parameters.

Perimenopause

During perimenopause, testosterone levels decline alongside estrogen. Some women experience low libido, fatigue, and changes in body composition that feel distinct from mood or sleep disruption. Testosterone therapy in this group is off-label and under-studied compared with postmenopausal populations. A 2023 systematic review in Climacteric found limited high-quality evidence for testosterone in perimenopausal women specifically. Adding AOD-9604 on top of an already evidence-thin testosterone regimen compounds the uncertainty.

Post-Menopause

This is the life stage with the most testosterone trial data in women. The ISSWSH and Menopause Society position statements support consideration of testosterone for HSDD in post-menopausal women when other causes have been excluded. Body composition concerns, including visceral adiposity that accelerates after menopause, are real and clinically meaningful. AOD-9604 is sometimes pitched as an adjunct here. The monitoring framework above applies in full, with particular attention to cardiovascular risk factors that cluster in the postmenopausal decade.

Monitoring Protocol for Women Using Both Agents

No formal monitoring guideline exists for this combination, because no regulatory body has evaluated it. The following represents a clinical minimum derived from individual compound safety data and general endocrine monitoring standards.

Before starting:

• Total and free testosterone by LC-MS/MS (not immunoassay)
• Estradiol
• CBC with differential and hematocrit
• Fasting lipid panel
• Fasting glucose and HbA1c
• Liver function tests (testosterone is hepatotoxic at high doses, particularly oral forms)
• Blood pressure

At 3 months:

• Repeat testosterone level timed to dosing (e.g., peak and trough for injectables)
• Hematocrit (stop testosterone if hematocrit exceeds 54% per FDA guidance)
• Fasting lipid panel
• Fasting glucose
• Clinical assessment of androgenic side effects: acne, hair loss, voice changes, clitoral size

At 6 months and every 6 months thereafter:

• Full panel as above
• Review body composition by DEXA or validated clinical measure if available
• Reassess indication for both agents

If hematocrit rises more than four percentage points from baseline, or exceeds 50% in a woman, testosterone dose should be reduced and the prescriber should consider phlebotomy or discontinuation before the FDA threshold of 54% is reached. Women are not a separate footnote in hematocrit monitoring. The same erythropoietic mechanism applies.

What the Evidence Gap Means for You

Women have been historically under-represented in the clinical trials that would answer these questions directly. The Metabolic Pharmaceuticals AOD-9604 trials did not publish sex-stratified outcomes. Most testosterone pharmacokinetic studies in women are secondary analyses of trials designed around male physiology. The NIHR review on peptide research gaps acknowledges that peptide therapeutics remain poorly characterized in female populations across reproductive life stages.

This is not a reason to avoid all inquiry. It is a reason to demand transparency from anyone prescribing these agents, including honest statements about what is known versus extrapolated. Any clinician who presents this combination as "safe and well-studied" for women is misrepresenting the evidence. The monitoring framework above is how you protect yourself inside that evidence gap.